Charles D. Blanke

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance)

(2023)10.1158/1078-0432.c.6529877

Top 100%

0DataRank

Top 100%0 citations

Alexander B. Sibley, Sushant Patil, Amy S. Etheridge, Chen Jiang, Fang‐Shu Ou +15 more

Papers

Driven by 48 papers — median percentile 0. Top paper: “Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)”.

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002990

N/A

4.8DataRank · unranked

160 citations

Megan Othus, Sandip Pravin Patel, Chris Ryan, Ashish Sangal, Benjamin Powers +15 more

A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2182

N/A

3.8DataRank · unranked

125 citations

Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze +23 more

Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009074

N/A

0.503DataRank · unranked

12 citations

Megan Othus, Young Kwang Chae, Tridu R. Huynh, Benjamin Tan, Timothy M. Kuzel +9 more

SWOG 1609 cohort 48: anti–CTLA‐4 and anti–PD‐1 for advanced gallbladder cancer

Cancer(2024)10.1002/cncr.35243

N/A

0.496DataRank · unranked

15 citations

Elizabeth Guadarrama, Young Kwang Chae, Michael J. Dennis, Benjamin Powers, Chih‐Yi Liao +9 more

Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009128

N/A

0.380DataRank · unranked

9 citations

Megan Othus, Sandip Pravin Patel, Benjamin Powers, Chung-Tsen Hsueh, Rangaswamy Govindarajan +11 more

Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma

npj Precision Oncology(2025)10.1038/s41698-024-00798-1

N/A

0.303DataRank · unranked

5 citations

Eleanor Cano-Linson, Young Kwang Chae, Shiruyeh Schokrpur, Christopher D. Lao, Benjamin Powers +13 more

Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma)

Therapeutic Advances in Medical Oncology(2024)10.1177/17588359241293401

N/A

0.104DataRank · unranked

1 citations

Megan Othus, Sandip Pravin Patel, David E. Gerber, Tawee Tanvetyanon, Hye Sung Kim +10 more

Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.4003

N/A

0DataRank · unranked

3 citations

Qian Shi, Charles S. Fuchs, Donna Niedzwiecki, Tyler Zemla, Priya Kumthekar +15 more

Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9576

N/A

0DataRank · unranked

2 citations

Vassiliki A. Papadimitrakopoulou, Katherine Minichiello, David R. Gandara, Fred R. Hirsch, Philip C. Mack +14 more

Cancer Clinical Trial Participation at the 1-Year Anniversary of the Outbreak of the COVID-19 Pandemic

JAMA Network Open(2021)10.1001/jamanetworkopen.2021.18433

N/A

0DataRank · unranked

55 citations

Hong Xiao, Michael LeBlanc, Dawn L. Hershman, Charles D. Blanke, Joseph M. Unger

Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405

JNCI Journal of the National Cancer Institute(2021)10.1093/jnci/djab200

N/A

0DataRank · unranked

45 citations

Sui Zhang, Fang‐Shu Ou, Chao Ma, Nadine J. McCleary, Donna Niedzwiecki +16 more

Racial differences in survival and response to therapy in patients with metastatic colorectal cancer: A secondary analysis of CALGB/SWOG 80405 (Alliance A151931)

Cancer(2021)10.1002/cncr.33649

N/A

0DataRank · unranked

14 citations

Jun He, Jennifer Le‐Rademacher, Fang‐Shu Ou, Andrew Dodge, Tyler Zemla +8 more

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)—NRG-GI004/SWOG-S1610.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps3618

N/A

0DataRank · unranked

7 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +10 more

NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.tps158

N/A

0DataRank · unranked

4 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +10 more

Prognostic value of tumor deposits in stage III colon cancer patients, a post-hoc analysis of CALGB/SWOG 80702 phase III study.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.10

N/A

0DataRank · unranked

0 citations

Qian Shi, Jeffrey P. Meyers, Zhaohui Jin, Magali Svrcek, Charles S. Fuchs +14 more

Immune signatures to affect overall survival (OS) and response to bevacizumab (Bev) or cetuximab (Cet) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3515

N/A

0DataRank · unranked

0 citations

Akram Yazdani, Xueping Qu, Fang‐Shu Ou, Scott Van Buren, Omar Kabbarah +5 more

Influence of dietary insulin scores on survival in patients with metastatic colorectal cancer (mCRC): Findings from CALGB (Alliance) 80405.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3568

N/A

0DataRank · unranked

0 citations

Chao Ma, Fang‐Shu Ou, Chen Yuan, Brendan J. Guercio, Vicente Morales‐Oyarvide +15 more

Does adjuvant chemoradiation benefit patients with lymph node-positive biliary tract cancer? A secondary analysis of SWOG S0809.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4104

N/A

0DataRank · unranked

0 citations

Mai T. Duong, David P. Horowitz, Katherine A. Guthrie, Edgar Ben‐Josef, Anthony B. El-Khoueiry +5 more

National impact of the COVID-19 pandemic on clinical trial staff attrition: Results of the SWOG Cancer Research Network Survey of Oncology Research Professionals.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.11049

N/A

0DataRank · unranked

12 citations

Connie M. Szczepanek, Daniel P. Petrylak, Dana B. Sparks, Catherine M. Tangen, Primo N. Lara +3 more

NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.tps232

N/A

0DataRank · unranked

4 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +10 more

Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)—NRG-GI004/SWOG-S1610.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps3647

N/A

0DataRank · unranked

4 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +11 more

Representativeness of patients enrolled in the Lung Cancer Master Protocol (Lung-MAP).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.6543

N/A

0DataRank · unranked

0 citations

Joseph M. Unger, Qian Lü, Katherine Minichiello, Roy S. Herbst, David R. Gandara +14 more

1469 A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic disease

(2022)10.1136/jitc-2022-sitc2022.1469

N/A

0DataRank · unranked

0 citations

Megan Othus, Young Kwang Chae, Michael J. Dennis, Sarah Gordon, David G. Mutch +7 more

A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-2293

N/A

0DataRank · unranked

27 citations

Megan Othus, Young Kwang Chae, Michael J. Dennis, Sarah Gordon, David G. Mutch +9 more

Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0447

N/A

0DataRank · unranked

10 citations

Chao Ma, Chen Yuan, Qian Shi, Brian M. Wolpin, Yin Zhang +19 more

Adjuvant Chemoradiation in Patients with Lymph Node-Positive Biliary Tract Cancers: Secondary Analysis of a Single-Arm Clinical Trial (SWOG 0809)

Annals of Surgical Oncology(2023)10.1245/s10434-022-12863-9

N/A

0DataRank · unranked

13 citations

Sarah Colby, David P. Horowitz, Katherine A. Guthrie, Edgar Ben‐Josef, Anthony B. El-Khoueiry +6 more

Novel Approach to Accelerate Lung Cancer Research: Lung-MAP and the Potential of Public-Private Partnerships

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-2690

N/A

0DataRank · unranked

5 citations

Charles D. Blanke, Ellen V. Sigal, Roy S. Herbst

Physical activity in recurrent colon cancer: Cancer and Leukemia Group B/SWOG 80702 (Alliance)

Cancer(2023)10.1002/cncr.35007

N/A

0DataRank · unranked

4 citations

Chao Ma, Qian Shi, Tyler Zemla, Félix Couture, Philip Kuebler +11 more

A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The vulvar cancers.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5517

N/A

0DataRank · unranked

4 citations

Megan Othus, Sandip Pravin Patel, Robert P. Edwards, Jennifer Scalici, Liam Il‐Young Chung +8 more

NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps258

N/A

0DataRank · unranked

1 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +11 more

Data from Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab

(2023)10.1158/1078-0432.c.6532436

N/A

0DataRank · unranked

0 citations

Akram Yazdani, Naim U. Rashid, Xueping Qu, Fang‐Shu Ou, Scott Van Buren +7 more

Data from A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

(2023)10.1158/1078-0432.c.6530837

N/A

0DataRank · unranked

0 citations

Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze +23 more

Data from Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance)

(2023)10.1158/1078-0432.c.6529877

Top 100%

0DataRank

Top 100%0 citations

Alexander B. Sibley, Sushant Patil, Amy S. Etheridge, Chen Jiang, Fang‐Shu Ou +15 more

Data from Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance)

(2023)10.1158/1078-0432.c.6529877.v1

Top 100%

0DataRank

Top 100%0 citations

Alexander B. Sibley, Sushant Patil, Amy S. Etheridge, Chen Jiang, Fang‐Shu Ou +15 more

A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART SWOG 1609) in patients with refractory gallbladder cancer (cohort 48).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e16330

N/A

0DataRank · unranked

0 citations

Elizabeth Guadarrama, Young Kwang Chae, Chih‐Yi Liao, Anup Kasi, Grace R. Tarabay +12 more

A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The desmoid tumors (cohort 27).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.11516

N/A

0DataRank · unranked

0 citations

Megan Othus, Sandip Pravin Patel, Benjamin Powers, Chung-Tsen Hsueh, Rangaswamy Govindarajan +10 more

Plant-based diet and survival among patients with metastatic colorectal cancer

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae213

N/A

0DataRank · unranked

15 citations

Fang‐Shu Ou, Clare A. Gatten, Chao Ma, Alan P. Venook, Heinz‐Josef Lenz +8 more

SWOG/NCI Phase II Dual Anti–CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0606

N/A

0DataRank · unranked

11 citations

Megan Othus, Sandip Pravin Patel, Kelly J. Wilkinson, Emily M. Whitman-Purves, Jayanthi Lea +21 more

A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1957

N/A

0DataRank · unranked

6 citations

Lucy Corthell, Sandip Pravin Patel, Robert P. Edwards, Jennifer Scalici, Hye Sung Kim +10 more

A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort

Cancer Communications(2025)10.1002/cac2.70020

N/A

0DataRank · unranked

3 citations

Megan Othus, Sandip Pravin Patel, Raid Aljumaily, Khine Z. Win, Tanya Pejovic +12 more

Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol

The Lancet Oncology(2020)10.1016/s1470-2045(20)30475-7

N/A

0DataRank · unranked

125 citations

Vassiliki A. Papadimitrakopoulou, Katherine Minichiello, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +21 more

Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance)

European Journal of Cancer(2025)10.1016/j.ejca.2025.115694

N/A

0DataRank · unranked

1 citations

Bert H. O’Neil, Sebastian Stintzing, Fang‐Shu Ou, Tyler Zemla, Donna Niedzwiecki +18 more

Association of Patient Demographic Characteristics and Insurance Status With Survival in Cancer Randomized Clinical Trials With Positive Findings

JAMA Network Open(2020)10.1001/jamanetworkopen.2020.3842

N/A

0DataRank · unranked

48 citations

Charles D. Blanke, Michael LeBlanc, William E. Barlow, Riha Vaidya, Scott D. Ramsey +2 more

Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405

JNCI Cancer Spectrum(2020)10.1093/jncics/pkaa024

N/A

0DataRank · unranked

13 citations

Sui Zhang, Alan P. Venook, Fang‐Shu Ou, Donna Niedzwiecki, Heinz‐Josef Lenz +15 more

IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405

JNCI Cancer Spectrum(2020)10.1093/jncics/pkaa074

N/A

0DataRank · unranked

9 citations

Sui Zhang, Fang‐Shu Ou, Alan P. Venook, Donna Niedzwiecki, Heinz‐Josef Lenz +17 more

Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance)

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2021

N/A

0DataRank · unranked

27 citations

Alexander B. Sibley, Sushant Patil, Amy S. Etheridge, Chen Jiang, Fang‐Shu Ou +15 more

Enrollment of adolescents and young adults onto SWOG cancer research network clinical trials: A comparative analysis by treatment site and era

Cancer Medicine(2020)10.1002/cam4.2891

N/A

0DataRank · unranked

25 citations

Joseph M. Unger, Ann M. O’Mara, Mark A. Lewis, Troy Budd, Rebecca H. Johnson +4 more

A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG-GI004/SWOG-S1610).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.4_suppl.tps260

N/A

0DataRank · unranked

4 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +10 more

Charles D. Blanke

Indexed papers

Top data-sharing exemplar

Papers